Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adverse Event Reporting Included In Draft Electronic Health Record Standards

This article was originally published in The Pink Sheet Daily

Executive Summary

A draft proposal for stage 3 of standards that health care professionals must meet to demonstrate meaningful use of electronic health records includes an adverse event reporting requirement. Janet Woodcock has highlighted adverse event reporting as an area where the agency hopes to interface with EHRs.

You may also be interested in...

PDR Network Following FDA Wishlist In Program That Verifies EHRs Have Drug Safety Operations

PDR Network offers a certification program for electronic health records that is focused on drug safety. EHR vendors that demonstrate certain functions will be able to include a “PDR Certified” logo on their websites and other marketing materials, acknowledging a number of features FDA wants to see incorporated into EHRs.

EHRs Become A Stronger Research Tool Under Proposed Stage 2 Meaningful Use Rule

Use of electronic health records to report data to disease registries, for both cancer and non-cancer conditions, becomes an optional objective for providers to demonstrate “meaningful use” of EHRs under CMS’ proposed stage 2 requirements. An objective to identify patients for potential research opportunities also carries over to the stage 2 proposal.

EHRs A Tool For Drug Label Communications, Adverse Event Reporting And Adherence – FDA’s Woodcock

FDA’s vision for electronic health records is being incorporated into a new application launched by PDR Network.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts